NCT00006013

SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma

Phase II Trial of SU5416 as Treatment for Refractory/Relapsed Multiple Myeloma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Fox Chase Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: SU5416 may stop the growth of multiple myeloma by stopping blood flow to the cancer cells. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have refractory or relapsed multiple myeloma.

Detailed description

OBJECTIVES: I. Determine the response rate and response duration of patients with refractory or relapsed multiple myeloma treated with SU5416. II. Determine the toxicity of SU5416 in this patient population. OUTLINE: This is a multicenter study. Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues in the absence of unacceptable toxicity or disease progression. Patients are followed for survival. PROJECTED ACCRUAL: A total of 20-38 patients will be accrued for this study within 2 years.

Conditions

• Multiple Myeloma and Plasma Cell Neoplasm

Interventions

Type	Name	Description
DRUG	semaxanib

Timeline

• Start date: 2000-06-01
• Primary completion: 2003-01-01
• Completion: 2003-01-01
• First posted: 2003-06-25
• Last updated: 2013-07-11

Locations

4 sites across 1 country: United States